Tetrandrine, a novel inhibitor of ether-à-go-go-1 (Eag1), targeted to cervical cancer development

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Cancer remains a leading cause of global mortality.
• The Ether-à-go-go-1 (Eag1) ion channel is implicated in various aspects of cancer malignancy.
• Targeted inhibition of Eag1 is a critical area for cancer therapeutic development.

Purpose of the Study:

• To identify natural inhibitors of the Eag1 ion channel.
• To investigate the mechanism of action of tetrandrine on Eag1.
• To evaluate the therapeutic potential of tetrandrine in preclinical cancer models.

Main Methods:

• Direct interaction and electrophysiological assays to assess tetrandrine's effect on Eag1 currents.
• Site-directed mutagenesis to identify critical amino acids in Eag1's C-linker domain.
• Cell proliferation assays using HeLa and CHO cells expressing Eag1.
• In vivo studies using a mouse xenograft model of HeLa cell-transplanted tumors.

Main Results:

• Tetrandrine was identified as the first natural inhibitor of Eag1, with an IC50 of 69.97 ± 5.2 μM.
• Specific amino acids (Ile550, Thr552, Gln557) in the Eag1 C-linker domain were crucial for tetrandrine's inhibitory activity.
• Tetrandrine demonstrated dose-dependent inhibition of Eag1-expressing cell proliferation.
• Tetrandrine significantly inhibited tumor growth in mice, achieving a 64.21% reduction in HeLa cell-transplanted tumors.

Conclusions:

• Tetrandrine is a potent and selective inhibitor of the Eag1 ion channel.
• Tetrandrine exhibits preclinical efficacy in reducing cancer cell proliferation and tumor growth.
• Tetrandrine represents a promising lead compound for developing novel therapies against Eag1-related diseases.